SciSparc Ltd. has announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide $(PEA.AU)$. This innovative combination is designed to enhance pain and fever relief with lower doses and fewer side effects compared to paracetamol alone. By potentially offering a safer and more effective treatment option, the drug candidate aims to minimize risks like liver damage while improving outcomes for various types of pain and fever, marking a significant advancement in pain management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9458353-en) on May 27, 2025, and is solely responsible for the information contained therein.